

PRESS RELEASE - DECEMBER 2021

RESISTELL AG ANNOUNCES COMPLETION OF CLINICAL PILOT PERFORMANCE EVALUATION STUDY



Press release - December 2021

Resistell AG announces completion of clinical pilot Performance Evaluation Study

Resistell AG, the start-up developing the world's fastest phenotypic Antibiotic Susceptibility Test (AST) with its groundbreaking nanomotion technology platform has completed the pilot phase of its clinical Performance Evaluation Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity,

specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.

In the pilot study, the performance of Resistell AST was assessed for the most common bacteria/antibiotic combination, i.e. the most frequent cause of bacterial bloodstream infections at CHUV, *Escherichia coli* and the beta-lactam antibiotic ceftriaxone. Thirty patients from CHUV volunteered to participate in the study. Resistell AST proved 100% accurate with both comparators. It provided results within 4 hours compared to 11 and 17 hours by Vitek2 and Kirby-Bauer, respectively.

"To assess the antibiotic susceptibility by looking at bacterial nanomotion rather than bacterial growth is a complete change of paradigm that drastically reduces time to results without any apparent loss in quality so far. This new technology has the potential to largely improve patient care and have a major clinical impact in subjects with sepsis, by reducing the time to a tailored antibiotic treatment" says Prof. Gilbert Greub, Head of Microbiology Diagnostics at

CHUV, the Principal Investigator of this clinical study.

The study is supported in part by InnoSuisse. CRO Hemex supported Resistell and the CHUV team.

The remainder of the study will include additional bacteria and antibiotic combinations and is expected to conclude by end of 2022. To comply with the upcoming IVDR regulation, the study will be expanded to include additional hospitals in 2022. Once the PES is completed, Resistell can enter the diagnostic market and enable patients with bloodstream infections and sepsis to receive the optimal medication sooner, saving lives and changing the future of diagnostics.

For more information about our press release, please contact:

 **Dr. Danuta Cichocka**
 danuta.cichocka@resistell.com



About Resistell

Resistell is a deep-tech start-up addressing the problem of excessive time to results in Antimicrobial Susceptibility Testing (AST). Antimicrobial Resistance (AMR) is one of the biggest global health challenges. Resistell's nanomotion diagnostic device proposes an alternative to culture based antibiograms, the current gold standard in AST. Resistell's rapid AST method is based on the detection of vibration caused by living bacteria. Because the test is growth independent, the Resistell device reduces the time to result from days to a few hours. Resistell AST saves lives by finding the right antibiotic on time and reducing the spread of antibiotic resistance. For more information, visit <https://resistell.com/>

We thank for support:



